Radiopharm Theranostics Ltd. RADX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 109 cents this year.
The 3-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 |
| EBITDA $B | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | ◌ | ◌ | −0.0 |
| EPS, diluted $ | −1.76 | −12.41 | −11.32 |
| Dividend / sh $ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — |
| ROE % | −109.2 | −131.5 | −75.9 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
No fiscal year had a computed check that closed clean. 32 checks were skipped: the balance sheet is not tagged before 2023. 17 checks were skipped: cost of revenue is not tagged before 2024. 15 checks were skipped: EPS is not tagged before 2022.